Onco360 Selected to Distribute ZENBEXUS
Bristol-Myers Squibb has named the specialty pharmacy as a provider for its multiple myeloma treatment.
Updated on Sept. 22, 2026 in Cancer

Onco360 has joined the limited dispense network for ZENBEXUS, a therapy designed for adult patients with multiple myeloma. The drug, which requires at least one prior line of therapy, is distributed through a restricted Risk Evaluation and Mitigation Strategy program.
Why it matters
The pharmacy selection expands access to ZENBEXUS, which carries significant safety risks including thromboembolism and embryo-fetal toxicity. Its mechanism involves binding to cereblon to facilitate the degradation of Ikaros and Aiolos.
The EXCALIBER-RRMM trial results showed a 41% MRD-negative CR rate among 207 patients in the IberDd arm, compared to a 21% rate in the 213-patient DVd group. The drug is administered at a 1 mg dosage.
The players
Onco360
This specialty pharmacy headquartered in Louisville, Kentucky, provides distribution services for complex oncology medications.
Bristol-Myers Squibb
This global biopharmaceutical company based in Princeton, New Jersey, researches and manufactures treatments for serious diseases.
The details
Onco360, based in Louisville, Kentucky, will manage the specialized distribution of the medication developed by Bristol-Myers Squibb. Because of the drug's potent biological effects, providers must strictly adhere to safety protocols enforced by the REMS program.
Timeline
Onco360 was founded in 2003.
Trial results for EXCALIBER-RRMM were published in 2025.
Onco360 selection as a pharmacy provider was announced on September 21, 2026.
The Big Picture
This pharmacy rollout follows the clinical benchmarks set by the EXCALIBER-RRMM clinical trial. It represents a strategic step in translating high-efficacy trial data into regulated, patient-specific delivery systems.
Patients prescribed ZENBEXUS will work directly with specialty pharmacy coordinators to navigate the mandatory safety requirements. This ensures that patients understand the risks of embryo-fetal toxicity and thromboembolism while adhering to their prescribed treatment plan.
The takeaway
The integration of specialty pharmacies into restricted drug networks is vital for managing high-risk oncology therapies. Patients should maintain open communication with their care providers to ensure adherence to safety protocols required for complex multiple myeloma treatments.
Further reading
For more information on current treatment landscapes, visit the Cancer section.
More information
Review the full Onco360 specialty pharmacy information to understand distribution protocols.
Source note: This article includes information reported by Firstwordpharma.






